← All stocks

Taysha Gene Therapies, Inc.

TSHA Net selling

CIK 0001806310 #2058 in the set updated 18 Sep 2026

Bought (12 mo)

$0.00

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$6.66M

$1.25M on a plan · $3.53M straight out of an exercise

Sold at will

$1.88M

7 of 12 sales

Net

−$6.66M

−$1.88M against sales at will

By person

8 insiders · 12 transactions

28.0×

Sean Nolan holds 28.0 times base salary in stock. $18.15M of shares against $645.84K in salary for 2025.

Salary from the company's own proxy. The shares are what Sean Nolan last reported holding, valued at $6.24, the price Common Stock was last bought or sold at on the open market here, on 10 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Nagendran Sukumar

President and Head of R&D

—

$5.33M (7) scheduled

−$5.33M

936,410

0.2874%

$5.84M

+4.3%

Nolan Sean P.

Chief Executive Officer

—

$840.20K (2)

−$840.20K

2,908,257

0.8926%

$18.15M

+145.2%

Alam Kamran

CHIEF FINANCIAL OFFICER

—

$492.52K (3)

−$492.52K

1,442,131

0.4426%

$9.00M

+71.5%

Manning Paul B

10% owner

—

2,841,704

0.8721%

$17.73M

+35.9%

Stalfort John A III

Director

—

1,176,559

0.3611%

$7.34M

+7.1%

Donenberg Phillip B.

Director

—

241,289

0.0741%

$1.51M

+47.7%

Long Alison S

Director

—

127,178

0.0390%

$793.59K

+158.4%

Sepp-Lorenzino Laura

Director

—

127,178

0.0390%

$793.59K

+158.4%

Individual transactions

Insider

Date

Role

Action

Price

Amount

Nagendran Sukumar

10 Apr 2026

President and Head of R&D

Sold after exercise

200,000

$4.46

$892.00K

Nagendran Sukumar

12 Jan 2026

President and Head of R&D

Sold after exercise

200,000

$4.71

$942.00K

Nagendran Sukumar

1 Dec 2025

President and Head of R&D

Sold after exercise

260,047

$4.51

$1.17M

Nagendran Sukumar

28 Nov 2025

President and Head of R&D

Sold after exercise

110,125

$4.75

$523.09K

Show all 12 transactions →

What was left out

Form 4 filings counted 14

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 1

Sales straight out of an exercise 4

Sales at will 7

Transactions with no price 0

Shares from compensation/vesting 2,468,533

History held since 25 Sep 2020